Bruce C. Cozadd
including and Kathee. progress with XXXX the double and quarter. in the achievements evidenced you quarter. demand Overall, Defitelio third us. our afternoon strong sleep Thanks, We're pleased during for commercial Good R&D therapeutic portfolio third digit our hem/onc with our by Xyrem and experiencing performed and well growth joining and everyone thank significant during commercial areas
believe in to potential efficacy in While compelling of we light the its continue with Vyxeos, this challenges are for some we facing product data.
encountered ability We our current to new in address previously are and have confident challenges. results in hem/onc similar challenges products in the establishing
and approval the key hem/onc achieved FDA R&D milestones in in EU. Vyxeos authorization On with areas Xyrem our for the marketing side, we and narcolepsy both sleep therapeutic of in pediatric
regarding our the franchise. of the substantial We're JZP-XXX the study have additional pleased maximize in litigation provides clinical study our oxybate Xyrem of related study, to litigation resolution enhances value and of the completed of outstanding programs. advance put recruitment our Parkinson's Xyrem in also behind this We us. to IP solriamfetol clarity and to ability disease in The enrollment uncertainly multiple completed potential ongoing increased
the cash well development strong drive strategy long opportunities positioned growth company's in order of and over us investment to to position the sustainable corporate on to balancing Additionally, mid execute R&D our term. leaves
and I'll Matt regulatory Now financial activities Vyxeos then for the call turn provide of our our commercial, sales a in to over third further details some key R&D update. expectations and were on below quarter. the
in we we management. for central across of were utilization patients and adoption, continuum efficacy budget we increase at appropriate pleased Vyxeos patient key identified hospital some the leukemia While understanding clarify strengthen growth with to fit of as to order and wider and Vyxeos' the to to population the treaters, In chemotherapy. of intensive selection a address accounts, concerns barriers need encounter the continue of a adoption AML criteria therapy differentiated broader therapy secondary Vyxeos
accounts. are drive key to change approach We implementing an all through assertive
three, includes significant of plan and patients treaters to and standard Vyxeos; and by leaders how patient ensure Vyxeos understand, chemotherapy Vyxeos superiority leukemia NCCN the AML the education AML account the optimal X breadth one, that outcomes. outreach secondary opinion use by the as for in supported only two, key population category for full recommendation Our of to AML account to fully importantly, appropriate guidelines; and the
are for outreach new an into technology are considerable longstanding that payment of resulted has October also Vyxeos education aware changes that AML. continuing to add-on landscape and The practices to the for treatment AML environment We effective incorporate ensure in hospital administrators evolving X. which institutional budget became requires
arm. receive appropriate. Our patients use second of recent SOHO September, efforts had our months Vyxeos prolongation importance initial in also median therapy or AML Phase data XX.X poster whether transplantation a when Vyxeos stem believe X.X continuing received X presentation consolidation This in the meeting and data Vyxeos in induction consolidation after induction including patients At consolidation-specific emphasizing from study survival the the in a showed patients. transplantation. versus occurred to of without who a patients are secondary important cell optimal will X+X consideration months further for We followed their consolidation an for by the support in of as consolidation be consolidation of survival AML this overall
medical with and representatives our During the hem/onc science sales additional we liaisons. team third quarter, expanded
sales our believe we other will drive support launch and our hem/onc this to accounts. understanding is focused to rolling and reimbursement on we In and expanded team pricing is underway obtaining of also team expand to specialists, the reach AML the our Europe, reimbursement improved teams Together well remain of use positioned all key Our Vyxeos. with EUX. across
benefit access We we have in work place multiple to environment the Vyxeos. while P&R patient patients programs facilitate who from for complex access through can
children with acute meeting or the leukemia As the Vyxeos, month. XX of generate a relaxed data looking our forward X years in to of next additional adults up at efforts refractory Phase oral part ASH data to of lymphoma Vyxeos with we're study and age evaluating presentation from to
in We with evaluate have an other broadly in therapies. Vyxeos our AML targeted R&D made in progress building of efforts Vyxeos including understanding to combination more
and insights recruiting. of with to part study AML the fit X and Anderson, in current MD Vyxeos of combination will collaboration use began This outcomes of the novo studies combination agents. the contribute rationale chemotherapy Vyxeos patients study how refractory our maximize in one two recently for and have combination dose a offer Phase As on which continuing to intensive AML with relapsed into in evaluating schedule it additional will been de with posted is venetoclax clinicaltrials.gov, patients and
agent and a gemtuzumab to AML study failure start in is soon. refractory will with expected patients second after combination which or relapsed evaluate The hypomethylating Vyxeos MDS
chemotherapy XX and AML intend XXXX believe in in and XX AML studies bring expanding an for forward provides across step important cooperative to to in we ensuring MDS. evaluating the plus group including with pediatric of backbone optimizing and other standard adults, more value the studies as commitment therapy. risk We the agents, and Vyxeos progress are research relapsed benefit AML in and refractory Additionally, Vyxeos combination patients towards of
quarter believe are pleased in improving VOD. our educational the with of awareness third Turning Defitelio, physician and efforts and performance to we're of Defitelio the promotional
transplantation with defibrotide goal analysis well. been XXX versus either planned rare hematopoietic and X improving of The the the are We in the This making be progress of preparing the also Phase enrolling or has interim who XXX disease prevention will for in study study following enrollment develop predefined determine and we graft patients. acute development of analysis patients final is our interim will continue prevention enrollment VOD to host lives XXXX. strong for complications are Patient for our program. good of X the stem-cell Phase
actively of TA-TMA regulatory treatment Additionally for authorities we to and optimal to on collaborate continue protocol pivotal enrollment now the study with in expect begin development our for XXXX.
Finally NDA of our partner, an in in October Japan Nippon submitted treatment Shinyaku, the for VOD.
continued impact third challenges availability supply quarter. Erwinaze, For in product the to
Erwinaze Porton Health is agreement a license a and single PBL, is Limited, manufactured wholly from Biopharma Social reminder, Department a of the by Erwinaze or as our source. under UK Care we owned company PBL and by As that
midst the reliability with work to outage. seeking supply, been currently supply have PBL a we we of are in improve to global While of
supply While outages unfortunately resume this quarter into quarter, supply year. we further later the in we and to expect expect next
the at of treatment for control issues for actions We PBL of ongoing impact to maximize in this are ALL manufacturing the that continue patients ability Erwinaze we taking provide all our component and our committed to regimen important with to remain to disappointed availability negatively patients.
compared the third of of performance the our to strong area the sleep The X% to same the number quarter to with XXXX periods therapeutic and narcolepsy the on active with in period see oxybate of months year we volume same increased X% of number the diagnosed periods both JZP-XXX, compared program. in bottle third and sodium in in average of nine Now continue remained newly XXXX. the up first in quarter to in low growth Xyrem growth Xyrem to starting patients. XXXX, and Xyrem patients last XX,XXX
Our for age XX, narcolepsy supplemental pediatric first representing treatment patients NDA FDA approved for on the XX. Xyrem under approval for October received cataplexy
next pediatric in include of We to information caregiver implementation half specific modification the and to this year first in to launch the of expect following a populations. REMS indication
and JZP-XXX end. On We Phase excessive sleepiness patients year cataplexy study recruitment September be of narcolepsy the continues to progress. randomization in to and withdrawal study daytime completed development adult X expect front, completed patient around in our with randomized
top X the for in idiopathic Xyrem. hypersomnia begin patent related line patients we is in quarter. patient site this JZP-XXX We to progress with randomized study withdrawal have expect We're enrollment the litigation Phase spring. in pleased Study results and outstanding evaluating activation will resolved expect to to share our
around the in dates economics resulting provide provided to could settlement substantially under timeline be generic entry for increased and with launch our clarity agreements the the certain and circumstances, authorized settlements Jazz. accelerated generic us the While
the volume if a right receiving its from to will so. second through no the begin of entitled to AG AG receiving XXXX selling we've an it Xyrem in year of sales. of generic, license of has its quantity but XXXX. the Xyrem year the a to first it Three mentioned, Hikma, X, on XXXX royalties an each has Jazz single Xyrem license five through December increasing percentage As through filers the eight have elects AG to December generic to substantially July up to with generic each XXXX, royalties first authorized prior product of right these or filers XXXX, company AG equal and meaningful launch meaningful limited as thereafter. do filer, to during second the has volume launch REMS with digit product the as XX, AG a AG, an January Jazz of AG years Xyrem in longer the a REMS a the sell the low period, REMS to Each sell a to a to Hikma product of through have Xyrem July launch right for
these area. As and of franchise, the our of and contributions a we're our about our continuing JZP-XXX by investments oxybate therapeutic certainty Xyrem to on long-term settlements the expanding sleep provided increased result excited
forward to a this excessive sleepiness, later or an looking launching meaningful with EDS, to solriamfetol. option the patients of obstructive or apnea. for year, first decision and sleep to scheduling FDA narcolepsy on DEA Now quarter We're due this XXXX treatment living in daytime approval
strong Neurological toward are October. including American with U.S. at Association We and presence significant making progress recent launch, CHEST the our in meetings a scientific
recent EDS and and signs the including patients a This at apnea with expect their resources campaign of and information called A a by hired next consumer both sales symptoms can our EDS and expansion that team the was OSA partners force aimed launched of We've which survey well Poll, patients activities have reported Kind daily personal in response for on impact solriamfetol. sleep combined conducted associated The and driving recently Tired interactions. force with negative a as campaign sleep developed providing as EDS-related helping also people We year. work, Different Harris and will living recognize cover sleep to Jazz-sponsored Xyrem sales marketing education apnea. of
of to strategy Our and launch and solriamfetol's a narcolepsy will leveraging OSA efficacy high-volume foothold mechanism robust with on strong treaters. establish data action differentiated focus
We X,XXX universe, relationships patients, a existing manage comprised of call tremendous is the physicians Xyrem leverage have which OSA who narcolepsy manage our whom opportunity also in to current X,XXX patients. of approximately
year On the Parkinson's proof study X share early development for top-line completed EDS side, we results evaluating Phase from next disease. expect to solriamfetol and of our concept
other and evaluate notable a We in in date symptom, sleepiness progress continued year solriamfetol my conditions development made significant we expect To regulatory are next accomplishments. year. we've eager to is information up to debilitating and additional excessive the where share quarter with remarks, about our plans wrap the third development daytime to
new effort important to continue treatment. to will patient address As are year, Vyxeos with an uptake influencing outcomes that factors we out this in improve close working the we
achieve XXXX JZP-XXX the approval month, solriamfetol Phase X in of this commencement for our of the We of solriamfetol several in FDA idiopathic including hypersomnia an and MAA study of narcolepsy. milestones EU for EDS submission to expect and additional in in OSA
hard for Parkinson's multiple receipt the XXXX disease this of of our data and now study Phase Matt, development Our narcolepsy turn the solriamfetol you. I'll including call adult top-line EDS from foundation over Phase year milestones from for clinical of trial our work to for and JZP-XXX laid X has X patients. in
